Oxford Biodynamics completes flotation on AIM

9th December 2016

Biomarker spinout Oxford Biodynamics holds successful flotation on AIM.

Oxford University Innovation welcomes the news this week that one of its spinouts, Oxford Biodynamics, has successfully completed its flotation on London AIM. The company was spun out in 2007 to commercialise technological breakthroughs in a new generation of biomarkers for cancer and other diseases. Its main platform, EpiSwitch, utilises Biodynamics’ biomarker evaluating technology to increase the success rates of drugs pass Phase I clinical trials. The company raised £20m ahead of its flotation this week, and has been trading steadily around the 160p mark.

For more on Oxford Biodynamics, please visit: http://www.oxfordbiodynamics.com/

For more on the flotation, please visit Proactive Investors or Shares Magazine.

Press release sign up